• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的复制特征以及适配体靶向刺突蛋白(S蛋白)以阻断病毒进入的优势

Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry.

作者信息

Zheng Jun, Pang Qiuxia, Fu Zhaoying

机构信息

Yan'an Medical College, Yan'an University, Yan'an 716000, China.

出版信息

ACS Omega. 2025 Apr 21;10(16):15840-15851. doi: 10.1021/acsomega.4c10933. eCollection 2025 Apr 29.

DOI:10.1021/acsomega.4c10933
PMID:40321580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12044446/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus of the coronaviridae family. The virus enters the cell through binding to the corresponding receptor angiotensin-converting enzyme 2 (ACE2) on host cell membrane with the spike protein (S protein) on its envelope; thus, we can design inhibitors that bind the S protein to block the entry of the virus into cells. Aptamers are single stranded DNA or RNA molecules that can form specific three-dimensional structures and bind their target molecules with high affinity and specificity and thus are promising candidates for S protein inhibitors. This paper reviews the replication cycle and cell entry mechanisms of SARS-CoV-2 as well as the preparation principle and characteristics of aptamers, features a discussion of the advantages of using aptamers to target the S protein to prevent SARS-CoV-2 from infecting cells, and finally summarizes the research progress in S protein-blocking aptamers.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种冠状病毒科病毒。该病毒通过其包膜上的刺突蛋白(S蛋白)与宿主细胞膜上相应的受体血管紧张素转换酶2(ACE2)结合进入细胞;因此,我们可以设计与S蛋白结合的抑制剂来阻断病毒进入细胞。适体是可以形成特定三维结构并以高亲和力和特异性结合其靶分子的单链DNA或RNA分子,因此是S蛋白抑制剂的有前途的候选物。本文综述了SARS-CoV-2的复制周期和细胞进入机制以及适体的制备原理和特性,讨论了使用适体靶向S蛋白以防止SARS-CoV-2感染细胞的优势,最后总结了S蛋白阻断适体的研究进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4923/12044446/bcc5d793fcc7/ao4c10933_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4923/12044446/c29b082f325b/ao4c10933_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4923/12044446/c12d79290e48/ao4c10933_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4923/12044446/845d3a6e66f0/ao4c10933_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4923/12044446/bcc5d793fcc7/ao4c10933_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4923/12044446/c29b082f325b/ao4c10933_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4923/12044446/c12d79290e48/ao4c10933_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4923/12044446/845d3a6e66f0/ao4c10933_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4923/12044446/bcc5d793fcc7/ao4c10933_0004.jpg

相似文献

1
Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的复制特征以及适配体靶向刺突蛋白(S蛋白)以阻断病毒进入的优势
ACS Omega. 2025 Apr 21;10(16):15840-15851. doi: 10.1021/acsomega.4c10933. eCollection 2025 Apr 29.
2
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.多学科方法鉴定与人 ACE2 或 SARS-CoV-2 刺突蛋白结合的化合物,作为阻断 SARS-CoV-2-ACE2 受体相互作用的候选药物。
mBio. 2021 Mar 30;12(2):e03681-20. doi: 10.1128/mBio.03681-20.
3
Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.阻断 N-和 O-聚糖的合成可抑制 SARS-CoV-2 病毒进入。
Elife. 2020 Oct 26;9:e61552. doi: 10.7554/eLife.61552.
4
A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response.一种新的 DNA 适体可与 SARS-CoV-2 刺突蛋白结合并减少促炎反应。
Sci Rep. 2024 Mar 29;14(1):7516. doi: 10.1038/s41598-024-58315-0.
5
Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection.基于结构的双价适体阻断 SARS-CoV-2 感染的开发。
Molecules. 2023 Jun 8;28(12):4645. doi: 10.3390/molecules28124645.
6
In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.计算机模拟研究 SARS-CoV-2 刺突蛋白与血管紧张素转化酶 2 的关键结合模式。
Sci Rep. 2021 Mar 25;11(1):6927. doi: 10.1038/s41598-021-86380-2.
7
Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection.中和适体阻断S/RBD-ACE2相互作用并防止宿主细胞感染。
Angew Chem Weinheim Bergstr Ger. 2021 Apr 26;133(18):10361-10366. doi: 10.1002/ange.202100345. Epub 2021 Mar 22.
8
Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.关注的 SARS-CoV-2 变异株刺突突变对人类或动物 ACE2 介导的病毒进入和中和的影响。
Microbiol Spectr. 2022 Jun 29;10(3):e0178921. doi: 10.1128/spectrum.01789-21. Epub 2022 May 31.
9
Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells.人类 ACE2 基因多态性影响 SARS-CoV 和 SARS-CoV-2 进入细胞。
Microbiol Spectr. 2022 Aug 31;10(4):e0087022. doi: 10.1128/spectrum.00870-22. Epub 2022 Jul 11.
10
DNA Aptamers Block the Receptor Binding Domain at the Spike Protein of SARS-CoV-2.DNA适配体阻断严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的受体结合域。
Front Mol Biosci. 2021 Aug 12;8:713003. doi: 10.3389/fmolb.2021.713003. eCollection 2021.

本文引用的文献

1
Dimeric DNA Aptamers for the Spike Protein of SARS-CoV-2 Derived from a Structured Library with Dual Random Domains.源自具有双随机结构域的结构化文库的新冠病毒刺突蛋白二聚体DNA适配体
Small Methods. 2024 Dec 20:e2401600. doi: 10.1002/smtd.202401600.
2
Recent advances in aptamer discovery, modification and improving performance.适体发现、修饰及性能提升的最新进展。
Biochem Biophys Rep. 2024 Oct 24;40:101852. doi: 10.1016/j.bbrep.2024.101852. eCollection 2024 Dec.
3
Aptamer-Hytac Chimeras for Targeted Degradation of SARS-CoV-2 Spike-1.
靶向 SARS-CoV-2 刺突蛋白-1 的适体-Hytac 嵌合体
Cells. 2024 Oct 25;13(21):1767. doi: 10.3390/cells13211767.
4
Synthesis and study of surface-modified and anti-EGFR DNA aptamer -conjugated chitosan nanoparticles as a potential targeted drug delivery system.表面修饰且抗表皮生长因子受体(EGFR)DNA适配体偶联的壳聚糖纳米粒作为潜在靶向给药系统的合成与研究
Heliyon. 2024 Oct 5;10(19):e38904. doi: 10.1016/j.heliyon.2024.e38904. eCollection 2024 Oct 15.
5
The Assessment of Anti-SARS-CoV-2 Antibodies in Different Vaccine Platforms: A Systematic Review and Meta-Analysis of COVID-19 Vaccine Clinical Trial Studies.不同疫苗平台中抗SARS-CoV-2抗体的评估:一项关于COVID-19疫苗临床试验研究的系统评价和荟萃分析
Rev Med Virol. 2024 Nov;34(6):e2579. doi: 10.1002/rmv.2579.
6
A colorimetric reverse-transcription loop-mediated isothermal amplification method targeting the L452R mutation to detect the Delta variant of SARS-CoV-2.一种基于比色逆转录环介导等温扩增方法,针对 L452R 突变,用于检测 SARS-CoV-2 的 Delta 变异株。
Sci Rep. 2024 Sep 20;14(1):21961. doi: 10.1038/s41598-024-72417-9.
7
Fighting Mutations with Mutations: Evolutionarily Adapting a DNA Aptamer for High-Affinity Recognition of Mutated Spike Proteins of SARS-CoV-2.以突变对抗突变:通过进化使DNA适配体适应对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)突变刺突蛋白的高亲和力识别
Angew Chem Int Ed Engl. 2025 Jan 15;64(3):e202415226. doi: 10.1002/anie.202415226. Epub 2024 Nov 2.
8
Enhancing Immune Responses against SARS-CoV-2 Variants in Aged Mice with INDUK: A Chimeric DNA Vaccine Encoding the Spike S1-TM Subunits.使用INDUK增强老年小鼠对SARS-CoV-2变体的免疫反应:一种编码刺突S1-TM亚基的嵌合DNA疫苗。
ACS Omega. 2024 Jul 30;9(32):34624-34635. doi: 10.1021/acsomega.4c03285. eCollection 2024 Aug 13.
9
Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models.局部放疗联合 TIM-3 适体可改善弥漫性中线胶质瘤模型的存活率。
JCI Insight. 2024 Aug 15;9(18):e175257. doi: 10.1172/jci.insight.175257.
10
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19.考虑开发针对 COVID-19 新型病毒变异株的单克隆抗体。
Expert Opin Biol Ther. 2024 Aug;24(8):787-797. doi: 10.1080/14712598.2024.2388186. Epub 2024 Aug 6.